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Introduction and importance: Hajdu Cheney Syndrome (HCS) is a rare skeletal disease characterized by severe,
progressive focal bone loss with osteoporosis, variable craniofacial, vertebral anomalies and distinctive facial
features. It is inherited as an autosomal dominant disease although sporadic cases have been described in
literature. Identifying these cases in clinical practice is important for proper diagnosis and management.
Case presentation: We report a case of a 36-year-old male patient presented at metabolic bone disease clinic at the
Aga Khan University Hospital with history of multiple fragility fractures and juvenile osteoporosis since child
hood. DNA sequence analysis of the NOTCH2 coding sequence revealed a pathogenic variant in NOTCH 2, Exon
34, c.6426_6427insTT (p.Glu2143Leufs*5), consistent with a NOTCH2 related conditions including HCS.
Clinical discussion: The multitude of presentations associated with HCS are linked to the NOTCH2 gene, as Notch
signaling is one of the core signaling pathways that control embryonic development. Hence, mutations in the
Notch signaling pathway cause developmental phenotypes that affect various organs including the liver, skel
eton, heart, eye, face, kidney, and vasculature.
Conclusion: To the best of our knowledge, nucleotide mutations of c.6933delT, c.6854delA, c.6787C.T, and
c.6424-6427delTCTG were all determined to be novel, with c.6428T > C being the most common mutation found
in literature. The c.6426_6427insTT mutation our patient was found to have via gene sequencing too appears to
be a novel mutation, which has not previously been reported in literature.

1. Introduction
Hajdu Cheney Syndrome (HCS) is a rare skeletal disease character
ized by severe, progressive focal bone loss with osteoporosis, variable
craniofacial, vertebral anomalies and distinctive facial features. It is
inherited as an autosomal dominant disease although sporadic cases
have been described in literature [1]. There is marked phenotypic
variability and the degree of severity in clinical features between
affected individuals and hence it often remains undiagnosed until
adolescence or adulthood [2]. Thus, despite the fact that the disease
begins to manifest at birth, it is still extremely rare with fewer than one
hundred cases found in the literature [3].
The disease was linked to mutations in the Notch Receptor 2
(NOTCH2) gene in 2011 by whole-exome sequencing in individuals with

HCS. Specifically, mutations of exon 34 have been shown to remove
PEST domains, a peptide sequence that is rich in proline (P), glutamic
acid (E), serine (S), and threonine (T) due to a premature stop in amino
acid codon, creating a truncated and stable NOTCH2 protein with
enhanced NOTCH2 signaling activity [1,4–6]. Dysregulation of Notch
signaling is associated with skeletal developmental disorders and bone
remodeling, and gain-of-function mutations of NOTCH2 are associated
with HCS [3]. Notch receptors are single-pass trans membrane proteins
that determine cell fate and play a critical role in skeletal development
and homeostasis [3]. Furthermore, NOTCH2 is present in all embryonic
tissue and hence manifested as wide phenotype with a variety of clinical
manifestations, related to skeletal development & homeostasis [1].
Identifying these cases in clinical practice is important for proper
diagnosis and management. The unknown mechanism of disease
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hormone, and luteinizing hormone & free androgen index were also
within the reference intervals.
Based on history & facial dysmorphism, he was referred for geneticist
consult. DNA sequence analysis of the NOTCH2 coding sequence was
performed on genomic DNA extracted from peripheral leucocytes at the
Invitae Corporation, San Francisco CA 94103. A pathogenic variant in
NOTCH2, Exon 34, c.6426_6427insTT (p.Glu2143Leufs*5) heterozy
gous was identified, consistent with a predisposition to, or diagnosis of
NOTCH2 related conditions including HCS (MedGen UID: 182961) and
Alagille syndrome 2 (ALGS2) (MedGen UID: 341844).
Further inquiry revealed that the patient’s daughter has facial fea
tures resembling those of her father and a history of patent ductus
arteriosus (PDA), acroosteolysis. He also gave history of abortion of a
female fetus with cardiac developmental defect. Genetic testing was
advised for confirmation of the disease and subsequent management.
During his most recent follow-up visit, the patient was found to be
doing well. He was on Prolia and was advised weight reduction, lifestyle
measures, and exercise with stretch bands.

progression and bone loss amongst affected individuals poses a unique
therapeutic challenge. Continued research is critically important to
build on prior knowledge so that advancement related to drug devel
opment and treatment in the rare diseases of bone to improve bone
health can be made.
We present the first case diagnosed with HCS from our metabolic
bone disease clinic at Aga Khan University Hospital, Karachi, Pakistan.
We also performed a review of the literature to understand the pheno
typic and genotypic spectrum of the disease, and treatment regimens
utilized for its management. We searched the MEDLINE database for
studies with the search terms “NOTCH2” and “Hajdu Cheney Syndrome”
from 2012 to 2019 with English language restrictions. The title, abstract
and full text of all documents identified according to these search
criteria were scrutinized by the authors. Additionally, all references
found in the published articles were also reviewed for case report
ascertainment. This is an attempt to analyze the complete phenotype of
HCS for better understanding of the syndrome and contribute to an
earlier diagnosis in new cases. Further, it is also important for genetic
counselling. Written informed consent was obtained from the patient for
publication of this case report. This work has been reported in line with
the Case Report (CARE) guidelines [7,8].

3. Discussion
HCS was first reported by Hajdu and Kautze in 1948 [7] and later by
William D. Cheney in 1965 [9,10]. Prior to the molecular etiology of
HCS being discovered, Brennan et al. described 10 key clinical mani
festations of HCS including acroosteolysis, Wormian bones, Platybasia,
premature loss of teeth, micrognathia, coarse face, coarse hair, midface
flattening, short stature (<5%), and a positive family history [11]. He
also proposed a diagnostic tool on the basis of a series of physiological
parameters and genetic inheritance [11].
The search strategy adopted for the literature review to understand

2. Case report
A 36-year-old male patient presented at metabolic bone disease
clinic at the Aga Khan University Hospital with history of multiple
fragility fractures and juvenile osteoporosis since childhood. There was
no history of neurological or cardiovascular complications nor any uri
nary symptoms.
Upon physical examination, the patient’s height was 159 cm and
weight was 95 kg. He displayed a prominent forehead, hypertelorism,
long eyelashes, and micrognathia. Furthermore, his hands were short
and stubby with acroosteolysis and broad dark nails. There were no signs
of local inflammation in either fingers or toes. He had lost all his teeth
and had replaced them with dentures. The liver and spleen were not
palpable and no abnormalities were noted on cardiovascular and
neurological exams. Previous consultations in the United States of
America, during his childhood had considered the possibility of HCS due
to the presence of acroosteolysis. He had been taking bisphosphonates
including Pamidronate and Zoledronic Acid since childhood. He was on
Prolia when he presented this time.
Table 1 shows the results of bone biochemistry and Dual-energy Xray absorptiometry (DXA) findings at an interval of two years. Complete
blood count, serum electrolytes, liver and renal function tests (except
gamma-GT, which was marginally raised) were within the normal range
on different occasions. In addition, thyroid profile, follicle stimulating

Table 1
Results of bone biochemistry & DXA findings of the patient in 2019 & 2017.
Variable
Bone Biochemistry
Serum Calcium (8.6–10.2mg/dl)
Serum Phosphorus (2.5–4.5 mg/dl)
Serum Magnesium (1.6–2.6 mg/dl)
Serum 25-hydroxy vitamin D (>20ng/ml)
Serum 1,25-hydroxy vitamin D (19.9–79.3 pg/mL)
Parathyroid hormone (PTH) (16–87pg/ml)
Serum N-terminal telopeptide (NTx) (5.4–24.2 nMBCE/L)
DXA Findings
Left Hip
BMD
Z score
Femoral Neck (FN)
BMD
Z score
Spine
BMD
Z score
L (distal) forearm
BMD
Z score

2019

2017

9.3
3.3
1.7
36.1
–
59.9
13.93

9.4
2.9
2.0
31.9
46.7
55.5
16.69

0.863
− 1.0
0.646
− 1.7
− 4.4
− 4.3
0.617
− 3.6

0.866
− 1.1
0.666
− 1.6
0.598
− 4.5
0.649
− 2.9

Fig. 1. Consort showing the Selection of Manuscripts for Review on Hajdu
Cheney Syndrome.
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the phenotype and genotypic variability in patients with confirmed
NOTCH2 mutations is summarized in Fig. 1. Tables 2 and 3 shows the
full spectrum of phenotypic and radiological manifestations reported so
far with confirmed NOTCH2 mutations. Substantial phenotypic vari
ability amongst patients’ results in a syndrome that often remains un
diagnosed until adolescence or adulthood despite being congenital and
manifesting at birth. Furthermore, the plethora of clinical symptoms
leads to many potential differentials amongst physicians who are un
aware of this syndrome.
Acroosteolysis and osteoporosis are two most common radiographic
findings followed by Wormian bones & Platybasia. Acroosteolysis usu
ally develops after the first few years of life and progresses through
adulthood, while severe osteoporosis occasionally occurs with fishbone
deformity [12]. Although Acroosteolysis is a hallmark of HCS, it can also
be secondary to a variety of other disorders. These may include auto
immune disorders such as Scleroderma, Systemic Lupus Erythematous,
Rheumatoid Arthritis, and Raynaud’s Disease; or neuropathies such as
Diabetes Mellitus [13]. Other causes include trauma, burns, frostbite,
toxic steep (due to PVC or ergot poisoning), and infections [13].
The multitude of presentations associated with HCS are linked to the
NOTCH2 gene, as Notch signaling is one of the core signaling pathways
that control embryonic development [14]. Hence, mutations in the
Notch signaling pathway cause developmental phenotypes that affect
various organs including the liver, skeleton, heart, eye, face, kidney, and
vasculature. Gene sequencing has revealed a wide array of nucleotide
mutations and protein alterations associated with HCS (Table 4). These
differences and variability may also account for the diverse phenotypic
spectrum as seen in literature. To the best of our knowledge, nucleotide

Table 3
Radiographic Findings in Systems & their Frequency (n) in Hajdu Cheney Syn
drome with NOTCH2 Mutation Reported in Literature from 2012 to 2019.

Manifestation

Frequency
(n)

Craniofacial

Auricular Abnormalities
Retro/micrognathia
Coarse hair
Long philtrum, Down slanted palpebral fissures

21
20
14
13 cases
each
12
11
10 cases
each
9
5
3
2 cases each
1 case each
11
4
2 cases each

Dentition

Cardiovascular

Eye
Pulmonary

Renal
Other Findings

Hypertelorism
Synophrys
Bushy Eyebrows, Mid facial Hypoplasia, Thin
Lips
Wide nose, Cleft palate
Large head circumference
Prominent forehead
Down turned mouth, Telecanthus
Short nose, Pale skin, Small face
Loss of teeth
Malocclusion
Irregular wide-spaced teeth & Dental
hypermobility
Short roots of permanent teeth
PDA
Sub aortic stenosis
VSD, Coarctation of the aorta, Hypoplastic left
ventricle, Supraventricular tachycardia
Exophthalmos
Glaucoma, Myopia
Pneumonia, Upper airway obstruction
Pulmonary hypertension, Idiopathic pulmonary
hemosiderosis
Fibrosis of lungs
Renal cysts
Polycystic kidney disease
End stage renal disease
Hyploplasia of the nails, clubbed fingers,
Cryptorchidism
GI malrotation, Polyhydramnios, Inguinal hernia
Splenomegaly, Anterior crossbite, Psoriatic
arthritis

Manifestation

Frequency
(n)

HEAD

Wormian Bones
Platybasia/Basilar Invagination
Dilatation of ventricles
Open skull sutures, Bathrocephaly
Chiari malformation
Thin corpus callosum, Paranasal sinus
hypoplasia, Lack of frontal sinus
Scaphocephalus, Thin superior cerebellar
peduncles, Arachnoid cyst posterior fossa with
defect in occipital bone, Tympanic bone
incompletely formed, Irregular
temporomandibular joint
Acroosteolysis
Fracture of long bones
Brachydactyly
Fibular bowing (serpentine fibulae), Hallus
Valgus/Varus
Radial dislocation
Genu Valgus/Varus, Syndactyly, Hip dysplasia,
Clubbed foot, Low trauma fractures
Hip protrusion, Loss of normal femoral
epiphysis, Abnormal ankle mortise, Accessory
naviculae, Mild bowing of tibia, Planovalgus,
Pes Valgus, Pes Planus, Lordosis, Broad valgus
toes, Pes cavus, Cubitus valgus
Osteoporosis/osteopenia
Vertebral fractures
Scoliosis- kyphosis
Fishbone deformity
Syringomyelia, Sclerosis of anterior vertebral
endplates
Spondylolisthesis, Degenerative disk disease

17
10
6
5 cases each
3
2 cases each

LIMBS

SPINE

Table 2
Phenotypic findings by organ systems & frequency (n) in hajdu cheney syn
drome with NOTCH2 mutations reported in literature from 2012 to 2019.
Systems

Radiological
Findings

1 case each

23
7
6
5
3
2
1 case each

21
11
10
4
3 cases each
1

mutations
of
c.6933delT,
c.6854delA,
c.6787C.T,
and
c.6424-6427delTCTG were all determined to be novel, with c.6428T > C
being the most common mutation found in literature. The
c.6426_6427insTT mutation our patient was found to have via gene
sequencing too appears to be a novel mutation, which has not previously
been reported in literature.
At present, definitive or effective pharmacological treatment for HCS
is not available. The hallmark of the disease, however, is acroosteolysis
and osteoporosis and, even though the exact molecular mechanism of
bone loss is not yet known, bisphosphonate therapy is essentially
empirical. According to the current knowledge that the main mechanism
of bone disease is the activation of osteoclasts, through RANK activation,
antiresorptive rather than anabolic treatment seems to be more appro
priate; thus, most cases reported have been administered antiresorptive
medications. As shown by our review, bisphosphonate therapy
(Zoledronate, Pamidronate, and Alendronate), alone or as part of a
treatment regimen, has been consistently utilized to counteract the
progression of osteoporosis associated with the disease. Teriparatide and
Denosumab have also been utilized for the skeletal manifestations of the
syndrome. From what we were able to determine in our review, these
therapies may not offer as much therapeutic benefit as that of
Bisphosphonates (Table 5). This difference may likely be attributed to
the variation in dosing regimens, as well as a lack of adequate data
rather than simply being a measure of drug efficacy. Furthermore, our
review also found differences between the therapeutic benefit of
different Bisphosphonates. These results may, however, also be attrib
uted to different scan intervals, dosing regimens, and age of the patients.
As such, it is critical that further trials are done to determine the ideal
symptomatic therapy for this disease.
In HCS, mutations in the terminal exon of NOTCH2 lead to the cre
ation of a stop codon upstream of the PEST domain, responsible for
ubiquitination and degradation of Notch, leading to a persistence of

1
7
2
1 case each
4
1 case each
2 cases each
1 case each
1
6
1
1
3 cases each
2 cases each
1 case each
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Table 4
Spectrum of nucleotide mutations & protein alteration in notch 2 gene in patients with hajdu cheney syndrome reported from 2010 to 2019 (N = 32).
S. No.

Author et al. (ref)

Year

Country

No. of patients

Age at (years)

Gender

Nucleotide
Mutation

Protein
Alteration

1
2
3
4

Stathopoulos, I et al. [18]
Lee, G et al. [19]
Gu, J et al. [20]
Narumi, Y et al. [21]

2012
2013
2013
2013

Greece
Korea
China
Japan

1
1
1
6

5
6

Descartes, M et al. [22]
Han, M et al. [23].

2014
2015

USA
Korea

1
2

p.Pro2149Profs5X
p.Leu2148
p.Gln2208X
p.Gln2361X
p.Glu2137X
p. Pro2071AsnfsX4
p.Leu2148X
p.Leu2148X
p.Leu2148X
p.His2212Glnfs9
p.Q2285Rfs2294

Deprouw, C et al. [24]
Battelino, N et al. [25]
Giovani, A et al. [26]

2015
2016
2016

France
Slovenia
Italy

1
1
2

Q2223X C > T
c.6909dup
c.6667C > T

Not Reported
p.lle2304Hisfs9
p.Gln2223Ter

10

Sakka, S et al. [27]

2017

England

4

11
12
13
14

Lee, J et al. [28].
Swan, L et al. [29]
Midro, A et al. [30]
Pittaway J et al. [31]

2018
2018
2018
2018

Korea
Australia
Poland
England

1
1
1
5

F
M
F
F
F
F
F
M
F
F
M
F
F
M
F
M
F
M
M
F
F
M
M
F
F

c.6450delT
c.6443T > G
c.6622C > T
c.7081C > T
c.6409G > T
c.6190_6212dup
c.6428T > C
c.6428T > C
c.6428T > C
c.6933delT
c.6854delA

7
8
9

c.6902T.A
c.6662-6663delTG
c.6787C.T
c.6724_6725delAG
c.6787C > T
c.7066G > A
c.6424-6427delTCTG
c.7198C > T
Not Reported

p.Leu2301
p.Val2221GlufsX22
p.Gln2263
p.Ser2242
p.Gln2263
p.Ala2317Tr
p.Ser2142ArgfsX4
p.Arg2400X
p.Pro2149Argfs 2×

15

This study

2020

Pakistan

1

31
21
57
14
2
31
41
20
46
47
3
32
36
8
33
5
15
6
15
17
10
NA
9
6
8
24
37

M

c.6426_6427insTT

p.Glu2143Leufs*5

invagination causes neurologic complications, or thoracic deformities
that might lead to respiratory restriction. Due to the low prevalence and
the lack of quality of life information available about this syndrome, it is
difficult to assess the years of healthy host life.

Table 5
Treatment response of patients with HCS to various available anti-osteoporotic
drugs reported in literature.
Class of Drugs

Ref
No.

Treatment
Regimen

Scan
Interval
(Years)

Lumbar Spine T/Z Score
Before
Treatment

After
Treatment

4. Conclusion

PTH Analogue

5

Teriparatide

− 4.3

− 3.0

Monoclonal
Antibody
Bisphosphonates

9

Denosumab

− 4.2

9

Zoledronic
Acid
Pamidronate
Zoledronate
Pamidronate
Alendronate
Zoledronate
Zoledronate
Pamidronate
Pamidronate
Zoledronate
Pamidronate
Alendronate
Pamidronate

Not
Reported
Not
Reported
5

− 4.1

Not
Reported
− 0.7

2
3
6

− 3.1
− 3.4
− 1.9

− 2.6
− 2.4
0.1

1½
2½
6
1½
2½
3
6
8½

−
−
−
−
−
−
−
−

HCS due to NOTCH2 defect is an important differential diagnosis to
consider in cases with acroosteolysis, osteoporosis, and multiple
craniofacial anomalies. Gene testing can facilitate in reaching the cor
rect diagnosis. The goal of treatment is to reduce the associated symp
toms and to prevent osteoporotic fractures. To the best of our
knowledge, this is the first case of Hajdu Cheney Syndrome to date
which has been diagnosed and reported from Pakistan. This is not
necessarily indicative of a decreased prevalence, however, but instead of
a much larger issue regarding unavailability of the diagnostic tests in the
country, requiring out sourcing to foreign labs, adding to the cost that
has to borne by the family. Therefore, coupled with the rarity of the
disease itself and the vast phenotypic spectrum with which it presents,
the disorder can remain undiagnosed for years, especially in developing
countries, as clinical suspicion is not enough to determine diagnosis. The
resultant delay in treatment and management can lead to an overall
increase in morbidity. In light of this, it is imperative that proper
treatment and management strategies are devised alongside a structured
diagnostic criterion as well as increased availability of molecular testing
for rare diseases in Pakistan.

10
12

16

0.8
2.1
3.1
1.7
2.9
4.4
3.0
3.6

−
−
−
−
−
−
−
−

0.7
1.7
1.3
0.3
2.5
4.5
4.5
3.0

NOTCH2 signaling [1,4]. Hence NOTCH2 itself could be a future target
for management of the disease, which would counteract the underlying
pathophysiology of the disorder as opposed to the current symptomatic
treatment available. Experimental modalities to control Notch signaling,
including the use of antibodies to the Notch extracellular domain or its
ligands and the use of cell membrane-permeable peptides that interfere
with the formation of the Notch transcriptional complex [15,16] could
be considered as future experimental therapies for HCS. These ap
proaches, however, may result in severe unwanted events [17]. For
example, impaired Notch signaling has resulted in gastrointestinal
toxicity and vascular tumors in experimental animals [17]. Therefore,
further controlled trials are warranted to ensure the successful imple
mentation of a regimen better suited for the management of this disease.
Moreover, the prognosis of HCS further worsens when basilar
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[14] J. Mašek, E.R. Andersson [Internet], The Developmental Biology of Genetic Notch
Disorders, vol. 144, Development (Cambridge). Company of Biologists Ltd, 2017,
p. 1743–63. Available from: https://pubmed.ncbi.nlm.nih.gov/28512196/.
(Accessed 27 July 2020).
[15] S.W. Ryeom, The cautionary tale of side effects of chronic Notch1 inhibition
[Internet], J Clin Invest 121 (2011), p. 508–9. Available from: https://pubmed.
ncbi.nlm.nih.gov/21266769/. (Accessed 27 July 2020).
[16] R.E. Moellering, M. Cornejo, T.N. Davis, C Del Bianco, J.C. Aster, S.C. Blacklow, et
al., Direct inhibition of the NOTCH transcription factor complex [Internet], Nature
462 (7270) (2009 Nov 12), 182–8. Available from, https://pubmed.ncbi.nlm.nih.
gov/19907488/. (Accessed 27 July 2020).
[17] M. Yan, C.A. Callahan, J.C. Beyer, K.P. Allamneni, G. Zhang, J.B. Ridgway, et al.,
Chronic DLL4 blockade induces vascular neoplasms [Internet], Nature. Nature 463
(2010). Available from: https://pubmed.ncbi.nlm.nih.gov/20147986/. (Accessed
27 July 2020).
[18] I.P. Stathopoulos, G. Trovas, K. Lampropoulou-Adamidou, T. Koromila, P. Kollia,
N.A. Papaioannou, et al., Severe osteoporosis and mutation in NOTCH2 gene in a
woman with Hajdu-Cheney syndrome, Bone 52 (1) (2013 Jan 1) 366–371.
[19] G.H. Lee, S.Y. An, Y.B. Sohn, S.Y. Jeong, Y.S. Chung, An unusual presentation of
diabetic ketoacidosis in familial hajdu-cheney syndrome: a case report [Internet],
J. Kor. Med. Sci. 28 (11) (2013), 1682–6. Available from: https://www.ncbi.nlm.
nih.gov/pmc/articles/PMC3835515/. (Accessed 27 July 2020).
[20] J mei Gu, Y qiu Hu, H. Zhang, C. Wang, W wei Hu, H. Yue, et al. [Internet],
A Mutation in NOTCH2 Gene in a Chinese Patient with Hajdu-Cheney Syndrome,
vol. 80, Joint Bone Spine. Elsevier Masson SAS, 2013, 548–9. Available from: htt
ps://pubmed.ncbi.nlm.nih.gov/23566664/. (Accessed 27 July 2020).
[21] Y. Narumi, B.J. Min, K. Shimizu, I. Kazukawa, K. Sameshima, K. Nakamura, et al.,
Clinical consequences in truncating mutations in exon 34 of NOTCH2: report of six
patients with Hajdu-Cheney syndrome and a patient with serpentine fibula
polycystic kidney syndrome [Internet], Am. J. Med. Genet.Part A 161 (3) (2013
Mar), 518–26. Available from: https://pubmed.ncbi.nlm.nih.gov/23401378/.
(Accessed 27 July 2020).
[22] M. Descartes, K. Rojnueangnit, L. Cole, A. Sutton, S.L. Morgan, L. Patry, et al.,
Hajdu-Cheney syndrome: phenotypical progression with de-novo NOTCH2
mutation [Internet], Clin. Dysmorphol. 23 (3) (2014) 88–94. Available from: htt
ps://pubmed.ncbi.nlm.nih.gov/24608068/. (Accessed 27 July 2020).
[23] M.S. Han, J.M. Ko, T.J. Cho, W.Y. Park, H Il Cheong, A novel NOTCH2 mutation
identified in a Korean family with hajdu-cheney syndrome showing phenotypic
diversity [Internet], Ann. Clin. Lab. Sci. 45 (1) (2015), 110–4. Available from: htt
ps://pubmed.ncbi.nlm.nih.gov/25696021/. (Accessed 27 July 2020).
[24] C. Deprouw, A. Feydy, J.S. Giraudet Le Quintrec, B. Ruiz, A. Kahan, Y. Allanore,
A very rare cause of acro-osteolysis: hajdu-Cheney syndrome [Internet], Jt Bone
Spine 82 (6) (2015), 455–9. Available from: https://pubmed.ncbi.nlm.nih.gov/
26184537/. (Accessed 27 July 2020).
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